Patents by Inventor Daniel Scheps
Daniel Scheps has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952601Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: GrantFiled: June 20, 2017Date of Patent: April 9, 2024Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Publication number: 20230346949Abstract: A method of forming a conjugate of a sulfonamide and a polypeptide, the method comprising: a) Providing an activated sulfonamide, wherein the activated sulfonamide corresponds to Formula (I); b) Providing an aqueous solution of a polypeptide having a free amino group, wherein the aqueous solution optionally comprises an alcohol; c) Contacting the aqueous solution of b) with the activated sulfonamide of a); and d) Reacting the activated sulfonamide with the polypeptide having a free amino group, obtaining a solution comprising the conjugate of a sulfonamide and a polypeptide, wherein the sulfonamide is covalently bonded to the polypeptide. Also associated conjugates, processes, procedures, proinsulins and the like.Type: ApplicationFiled: December 10, 2020Publication date: November 2, 2023Inventors: Thomas BOEHME, Marisa RAEDISCH, Manfred GERKEN, Oliver STEYER, Oliver BOSCHEINEN, Daniel SCHEPS, Hermut WEHLAN
-
Patent number: 11357821Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: December 9, 2019Date of Patent: June 14, 2022Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Juergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Publication number: 20220010294Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: ApplicationFiled: September 23, 2021Publication date: January 13, 2022Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Patent number: 11155802Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: GrantFiled: July 6, 2017Date of Patent: October 26, 2021Assignee: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen Frevert, Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps
-
Patent number: 11078472Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise (i) at least two random coil domains, or (ii) at least two domains having a polyproline II helix conformation, and the methods comprise the steps of inserting at least two nucleic acid sequences each coding for (i) a random coil domain, or (ii) a domain having a polyproline II helix conformation, into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising (i) the random coil domain-coding sequences, or (ii) the sequences encoding the domains having a polyproline II helix conformation in a host cell.Type: GrantFiled: January 19, 2017Date of Patent: August 3, 2021Assignee: Merz Pharma GmbH & Co., KGaAInventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Publication number: 20210008156Abstract: The invention relates to novel recombinant single-chain precursor botulinum neurotoxins serotype A comprising at least one additional domain and least one amino acid modification of the heavy chain of the neurotoxin. The novel recombinant single-chain precursor botulinum neurotoxins further comprises at least one cleavage site for a protease selected from the group consisting of thrombin, HRV3C, Tobacco Etch Vims protease, enterokinase and factor Xa. The invention further relates to novel recombinant botulinum neurotoxins serotype A exhibiting an increased duration of effect.Type: ApplicationFiled: October 26, 2017Publication date: January 14, 2021Inventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200354706Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said amino acid sequence consists of at least one proline and at least one alanine residue. The invention relates also to novel recombinant clostridial neurotoxins comprising at least one domain wherein said domain comprises an amino acid sequence consisting of at least 50 amino acid residues, wherein said domain comprises a plurality of specific amino acid repeats consisting of proline, alanine and tyrosine residues, or proline, alanine and glutamine residues, or proline, alanine and threonine residues.Type: ApplicationFiled: November 22, 2017Publication date: November 12, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200129587Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: ApplicationFiled: December 9, 2019Publication date: April 30, 2020Inventors: Juergen FREVERT, Fred HOFMANN, Michael SCHMIDT, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Publication number: 20200131494Abstract: This invention relates to novel recombinant botulinum neurotoxins serotype A exhibiting both (i) an increased duration of effect and (ii) a high specific biological activity. These novel recombinant botulinum neurotoxins comprise at least two additional domains consisting of proline, alanine and an additional amino acid residue and at least one amino acid modification which is located at the alpha-exosite or at the beta-exosite of the light chain of the neurotoxin. The invention further relates to novel recombinant single-chain precursor botulinum neurotoxins and compositions comprising the recombinant botulinum neurotoxin with an increased duration of effect and a high specific biological activity.Type: ApplicationFiled: July 6, 2017Publication date: April 30, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Jürgen FREVERT, Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS
-
Patent number: 10603353Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: GrantFiled: June 10, 2016Date of Patent: March 31, 2020Assignee: Merz Pharma GmbH & Co. KGaAInventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Publication number: 20200048624Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting an increased duration of effect without a delayed onset of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a domain consisting of proline, alanine, serine, threonine, glycine and glutamate residues, and the methods comprise the steps of inserting a nucleic acid sequence coding for said domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising said domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with an increased duration of effect without a delayed onset of effect.Type: ApplicationFiled: June 20, 2017Publication date: February 13, 2020Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Fred HOFMANN, Marcel JURK, Manuela LÓPEZ DE LA PAZ, Daniel SCHEPS, Jürgen FREVERT
-
Publication number: 20180327730Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise (i) at least two random coil domains, or (ii) at least two domains having a polyproline II helix conformation, and the methods comprise the steps of inserting at least two nucleic acid sequences each coding for (i) a random coil domain, or (ii) a domain having a polyproline II helix conformation, into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising (i) the random coil domain-coding sequences, or (ii) the sequences encoding the domains having a polyproline II helix conformation in a host cell.Type: ApplicationFiled: January 19, 2017Publication date: November 15, 2018Inventors: Fred Hofmann, Marcel Jurk, Manuela López De La Paz, Daniel Scheps, Jürgen Frevert
-
Publication number: 20180169182Abstract: This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.Type: ApplicationFiled: June 10, 2016Publication date: June 21, 2018Inventors: Jürgen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
-
Publication number: 20160201093Abstract: A process for preparing linear or branched primary alcohols with 3 to 13 carbon atoms from linear or branched alkanes with 3 to 13 carbon atoms by incubating a host organism having a functional P153 enzyme under elevated pressure in the presence of oxygen.Type: ApplicationFiled: July 21, 2014Publication date: July 14, 2016Applicant: BASF SEInventors: Michael Breuer, Boris Breitscheidel, Hans-Günter Wagner, Detlef Kratz, Bernhard Hauer, Daniel Scheps, Bernd Nebel
-
Publication number: 20160168597Abstract: A process for preparing 1-butanol from butane by incubating a host organism having a functional P153 enzyme under elevated butane pressure in the presence of oxygen.Type: ApplicationFiled: July 21, 2014Publication date: June 16, 2016Applicant: BASF SEInventors: Michael Breuer, Boris Breitscheidel, Hans-Günter Wagner, Detlef Kratz, Bernhard Hauer, Daniel Scheps, Bernd Nebel